Below are six instances of such deals:
- Sanofi on Jan. 27 agreed to manufacture more than 125 million doses of Pfizer’s COVID-19 vaccine.
- Novartis on Jan. 29 signed a deal to produce Pfizer’s COVID-19 vaccine.
- GlaxoSmithKline on Feb.3 agreed to make up to 100 million doses of CureVac’s COVID-19 vaccine candidate.
- Merck, which discontinued the development of both its COVID-19 candidates Jan. 25, on March 2 agreed to manufacture Johnson & Johnson’s COVID-19 vaccine.
- Novartis said March 4 it will manufacture CureVac’s COVID-19 vaccine candidate.
- Japanese drugmaker Takeda signed an agreement March 15 to use contract development and manufacturing company IDT Biologika’s facility, which was previously reserved for Takeda’s dengue vaccine candidate, to manufacture Johnson & Johnson’s COVID-19 vaccine.
More articles on pharmacy:
240 million Americans could get fully vaccinated against COVID-19 in 3 months
Aspirin linked to less severe COVID-19, fewer deaths, study shows
AstraZeneca says its vaccine was 79% effective against symptomatic COVID-19 in US trial
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
